Amorfix Life Science (ARFXF) 0.1140 $ARFXF ProMIS

New Post Public Reply Private Reply Replies (0) Message Board

Aug 30, 2016 at 11:16 AM

Amorfix Life Science (ARFXF) 0.1140 $ARFXF

ProMIS Neurosciences Announces Second Quarter 2016 Results
PRWeb - Fri Aug 12, 6:05AM CDT
Recent Corporate Highlights

ProMIS Neurosciences' Chief Science Officer Dr. Neil Cashman Presenting as an Invited Speaker at the 2016 Zing Propagation in Neurodegenerative Disease Conference
PRWeb - Thu Aug 11, 6:06AM CDT
ProMIS Neurosciences ("ProMIS" or the "Company"

, a company focused on the discovery and development of precision treatments for neurodegenerative diseases, announced that its Chief Science Officer Dr. Neil Cashman is presenting today as an invited speaker at the Zing Propagation in Neurodegenerative Disease Conference held in Dublin, Ireland between August 8-11, 2016. Dr. Cashman's oral presentation is entitled "Prion-like Propagation of SOD1 Misfolding in Amyotrophic Lateral Sclerosis (ALS)".

ProMIS Neurosciences Reports Highlights from the 2016 Alzheimer's Association International Conference
PRWeb - Wed Aug 03, 6:10AM CDT
ProMIS Neurosciences ("ProMIS" or the "Company"

, a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today reported highlights from the recent Alzheimer's Association International Conference (AAIC) meeting, held in Toronto, Canada, from July 23 to 28, 2016.

ProMIS Neurosciences Announces Results in Two Presentations at the 2016 Alzheimer's Association International Conference
PRWeb - Thu Jul 28, 6:05AM CDT
ProMIS Neurosciences ("ProMIS" or the "Company"

, a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced results in two presentations on its recent therapeutic developments at the Alzheimer's Association International Conference on July 27th, 2016 in Toronto, Ontario, Canada.

ProMIS Neurosciences Announces Identification of Multiple Product Candidates Targeting Alzheimer's Disease
PRWeb - Thu Jun 02, 6:09AM CDT
ProMIS Neurosciences ("ProMIS" or the "Company"

, a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced that multiple unique therapeutic candidates have successfully completed the screening stage of validation, and will be further developed as potential treatments for Alzheimer's disease (AD). These monoclonal antibody (mab) therapeutics selectively bind to distinct epitope targets specific for the neurotoxic, prion-like strains of misfolded Amyloid beta (Aβ), which are widely believed to play a key role in the development and progression of AD.

ProMIS Neurosciences announces identification of multiple product candidates targeting Alzheimer's disease
CNW Group - Thu Jun 02, 6:00AM CDT
Novel therapeutic candidates designed to specifically target the neurotoxic, prion-like strains of misfolded Amyloid beta
PMN.TO: 0.16 (unch)

ProMIS Neurosciences Announces First Quarter 2016 Results
PRWeb - Wed May 11, 6:10AM CDT
Recent Corporate Highlights

ProMIS Neurosciences announces first quarter 2016 results
CNW Group - Wed May 11, 6:00AM CDT
ProMIS Neurosciences, Inc. ("ProMIS" or the "Company"

today announced its operational and financial results for the three months ended March 31, 2016.
PMN.TO: 0.16 (unch)

ProMIS Neurosciences announces identification of a fourth novel therapeutic target for Alzheimer's disease
CNW Group - Thu May 05, 6:00AM CDT
Novel target is fourth in a series of potential targets on strains of misfolded Amyloid beta, implicated in the development and progression of Alzheimer's
PMN.TO: 0.16 (unch)

ProMIS Neurosciences to Present at the Toronto Microcap Conference
CNW Group - Tue Apr 05, 7:30AM CDT
The Microcap Conference is excited to announce that ProMIS Neurosciences (ticker: PMN.TO) will be presenting to investors on April 12th at the Hilton Toronto. ProMIS Neurosciences will also be available for one-on-one meetings with investors. The Microcap Conference aims to bring together a very selective group of high quality companies and some of the best investors in the micro-cap space. Registration as well as one-on-one scheduling is available at www.microcapconf.com.
PMN.TO: 0.16 (unch)

ProMIS Neurosciences, Inc. Completes First Tranche of its Private Placement
PRWeb - Wed Mar 30, 6:06AM CDT
ProMIS Neurosciences, Inc. ("ProMIS" or the "Company"

today announced that it has completed the first tranche of its non-brokered private placement (the "Private Placement"

(refer to the Company's February 23, 2016 press release). The Company issued a total of 10,803,676 common shares at $0.06 per share for gross proceeds of CDN $648,221.

ProMIS Neurosciences Announces FY2015 Year End Results
PRWeb - Wed Mar 23, 6:07AM CDT
Recent Corporate Highlights

ProMIS Neurosciences announces FY2015 year end results
CNW Group - Wed Mar 23, 6:00AM CDT
TSX: PMN
PMN.TO: 0.16 (unch)

Multiple Myeloma (Kahler Disease) Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/dldvmh/multiple_myeloma) has announced the addition of the "Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Myeloma (Kahler Disease) Overview - Therapeutics Development - Pipeline Products for Multiple Myeloma (Kahler Disease) - Overview - Pipeline Products for Multiple Myeloma (Kahler Disease) - Comparative Analysis - Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies - Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Myeloma (Kahler Disease) - Products under Development by Companies - Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Anthera Pharmaceuticals Inc. - APIM Therapeutics AS - APO-T B.V. - Arcarios BV - BioLineRx, Ltd. - Biotest AG - Bluebird bio, Inc. - DC Prime B.V. - Dicerna Pharmaceuticals, Inc. - Eli Lilly and Company - Enceladus Pharmaceuticals BV - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Immunomedics, Inc. - Immunomic Therapeutics, Inc. - Incyte Corporation - Inflection Biosciences Limited - Inventiva SAS - Jasco Pharmaceuticals, LLC. - NantKwest, Inc. - Nippon Kayaku Co., Ltd. - Nordic Nanovector ASA - OXIS International, Inc. - Panacela Labs, Inc. - Patrys Limited - Peptinov SAS - ProMIS Neurosciences Inc. - Quest PharmaTech Inc. - Rhizen Pharmaceuticals S.A. - Sphaera Pharma Pvt. Ltd. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synta Pharmaceuticals Corp. - XTL Biopharmaceuticals Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/dl...le_myeloma
IMMU: 2.76 (+0.05), DRNA: 3.31 (+0.01), INCY: 81.33 (unch), LLY: 78.14 (-0.46), STML: 8.71 (+0.01), SNTA: 0.34 (+0.07), ANTH: 3.00 (unch), EXEL: 11.01 (+0.03)

ProMIS Neurosciences Announces Identification of a Second Novel Therapeutic Target for Alzheimer's Disease
PRWeb - Wed Feb 03, 6:03AM CST
ProMIS Neurosciences is currently in the process of identifying and validating a series of potential targets (epitopes) specific to misfolded, propagating strains of Amyloid beta involved in Alzheimer's disease. The Company plans to use these targets to create specific monoclonal antibody therapeutics for Alzheimer's.

ProMIS Neurosciences announces identification of a second novel therapeutic target for Alzheimer's disease
CNW Group - Wed Feb 03, 6:00AM CST
Novel target is second in a series of potential targets on strains of misfolded Amyloid beta, implicated in the development and progression of Alzheimer's
PMN.TO: 0.16 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fuse Oncology Showcases New iRT Workflow at ASTRO

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Cut Winter Heating Costs with Townsend's Rebate Help

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

IASO's FUCASO Shows Robust Results in 2026 Study

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Quay Shines in 2026 Prescription Sunglasses Lineup

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

China Southern Airlines Marks 70th Anniversary in NYC

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Endurance Energy's Modular Tech Revs Up Southeast Asia

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

AST SpaceMobile Faces Class Action Over Misstatements

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

Farm Aid 2026: A Resilient Tribute to Family Farmers

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

Leo Cancer Care's Upright Radiotherapy Milestone

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...